{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:29:23Z","timestamp":1784204963175,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec><jats:title>\n<jats:sc>Background<\/jats:sc>\n<\/jats:title><jats:p>Gram\u2010positive bacterial infections are considered one of the major causes of mortality and morbidity in patients with cancer. Hence, the challenge lies in regulating the pervasive use of vancomycin in the management of infections facing such patients due to the anomalous vancomycin pharmacokinetics (PKs) and pharmacodynamics (PDs). Inappropriate vancomycin exposure is associated with toxicity, pathogen resistance, and therapeutic failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>\n<jats:sc>Objective<\/jats:sc>\n<\/jats:title><jats:p>The aim of this study was to estimate vancomycin PK in patients with cancer and without cancer. The standard dosage regimens of vancomycin were then evaluated using data from PK modeling.<\/jats:p><\/jats:sec><jats:sec><jats:title>\n<jats:sc>Methods<\/jats:sc>\n<\/jats:title><jats:p>In this observational PK study, the data were extracted from a matched patient cohort of those with cancer and those without cancer. Pharmacokinetic analysis was performed using Monolix version 4.4, and the PK parameters were compared in both groups (cancer vs noncancer). The standard and suggested vancomycin dosing regimens were evaluated using PK\/PD modeling and Monte Carlo Simulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>\n<jats:sc>Results<\/jats:sc>\n<\/jats:title><jats:p>In total, 448 blood samples were analyzed from 147 patients enrolled in this study, of which 73 patients had cancer and 74 patients were noncancer patients. In general, no significant differences were observed between the two groups (cancer vs noncancer) in all characteristics except for the vancomycin levels, which were significantly lower in patients with cancer (p\u00a0=\u00a00.00104). This analysis showed that patients with cancer showed a significantly higher vancomycin clearance than noncancer patients (p\u00a0=\u00a00.002), whereas the volume of distribution (V) was found to be similar in both groups (p\u00a0=\u00a00.83).This resulted in most of the patients failing to achieve the target area under the curve from zero to 24 hours (AUC<jats:sub>0\u20132<\/jats:sub>) to the minimum inhibitory concentration. These data showed that a higher maintenance dose of vancomycin is required to achieve the PD target.<\/jats:p><\/jats:sec><jats:sec><jats:title>\n<jats:sc>Conclusions<\/jats:sc>\n<\/jats:title><jats:p>The findings of this study showed that the patients with cancer have lower levels of vancomycin due to higher clearance than noncancer patients. Thus, higher doses than the standard vancomycin doses may be needed to treat invasive Methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> infections in patients with cancer.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2475","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T06:01:05Z","timestamp":1603260065000},"page":"1192-1200","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Optimization of Vancomycin Dosing Regimen in Cancer Patients using Pharmacokinetic\/Pharmacodynamic Modeling"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-8187","authenticated-orcid":false,"given":"Saeed","family":"Alqahtani","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University Riyadh Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit King Saud University Medical City Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almatrafi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University Riyadh Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit King Saud University Medical City Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Bin Aydan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University Riyadh Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit King Saud University Medical City Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshari","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University Riyadh Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit King Saud University Medical City Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Alzamil","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University Riyadh Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit King Saud University Medical City Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsultan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University Riyadh Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit King Saud University Medical City Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Asiri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"e99044","article-title":"Guidelines for therapeutic drug monitoring of vancomycin: a systematic review","volume":"6","author":"Ye ZK","year":"2014","journal-title":"PLoS One"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1078155209355847","article-title":"Pharmacokinetics of vancomycin in adult cancer patients","volume":"4","author":"Al\u2010Kofide H","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-019-02657-6","article-title":"The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults","volume":"7","author":"Bury D","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.5935\/0103-507X.20140003"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"e00420","DOI":"10.1002\/prp2.420","article-title":"Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations","volume":"4","author":"Monteiro JF","year":"2018","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak MJ","year":"2006","journal-title":"Clin Infect Dis"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"e112008","DOI":"10.1371\/journal.pone.0112008","article-title":"Vancomycin dosing in neutropenic patients","volume":"11","author":"Haeseker MB","year":"2014","journal-title":"PLoS One"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/600877"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_7_13_1","first-page":"e00088","article-title":"Population pharmacokinetic model for vancomycin used in open heart surgery: model\u2010based evaluation of standard dosing regimens","volume":"62","author":"Alqahtani SA","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10928-006-9043-z","article-title":"Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software","volume":"2","author":"Lavielle M","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s11096-019-00864-w","article-title":"Estimation of apparent clearance of valproic acid in adult Saudi patients","volume":"4","author":"Alqahtani S","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"e_1_2_7_16_1","first-page":"e02241","article-title":"Population pharmacokinetic model\u2010based evaluation of standard dosing regimens for cefuroxime used in coronary artery bypass graft surgery with cardiopulmonary bypass","volume":"62","author":"Alqahtani SA","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu398"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00005"},{"key":"e_1_2_7_19_1","unstructured":"The European Committee on Antimicrobial Susceptibility Testing.Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0 2020.http:\/\/www.eucast.org"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1369-5274(00)00132-6","article-title":"Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time","volume":"5","author":"Dudley MN","year":"2000","journal-title":"Curr Opin Microbiol"},{"issue":"27","key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijantimicag.2005.09.016","article-title":"Trough serum concentrations of \u03b2\u2010lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic\/pharmacodynamic properties of \u03b2\u2010lactams","volume":"2005","author":"Navas D","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1128\/AAC.00389-15","article-title":"Adequacy of high\u2010dose cefepime regimen in febrile neutropenic patients with hematological malignancies","volume":"59","author":"Sime FB","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/FTD.0000000000000250","article-title":"Evaluation of vancomycin prediction methods based on estimated creatinine clearance or trough levels","volume":"1","author":"Haeseker M","year":"2016","journal-title":"Ther Drug Monit"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.12.021"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.92"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000377652","article-title":"Augmented renal vancomycin clearance in cancer patients: a case report and review of the literature","volume":"4","author":"Curth HM","year":"2015","journal-title":"Oncol Res Treat"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.74"},{"key":"e_1_2_7_28_1","first-page":"823","article-title":"Enhanced renal clearance of vancomycin in rats with carcinogen\u2010induced osteosarcoma","volume":"3","author":"Shimada I","year":"2012","journal-title":"Anticancer Res"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:21Z","timestamp":1761058941000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/phar.2475"],"URL":"https:\/\/doi.org\/10.1002\/phar.2475","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"2020-11-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}